Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Parallel, Multicenter, Double-blind, Placebo-controlled Study to Investigate Efficacy and Safety of KP 001 in Patients Aged ≥2 Years With Common Venous Malformations, Common Lymphatic Malformations, or KTS/CLOVES Syndrome

NCT07285005 is registered in ClinicalTrials.gov with Kaken Pharmaceutical as lead sponsor.

NCT NCT07285005
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07285005 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Parallel, Multicenter, Double-blind, Placebo-controlled Study to Investigate Efficacy and Safety of KP 001 in Patients Aged ≥2 Years With Common Venous Malformations, Common Lymphatic Malformations, or KTS/CLOVES Syndrome
Lead sponsor
Kaken Pharmaceutical
Phase
Phase 3
Overall status
Recruiting
Start date
May 13, 2026
Completion date
February 29, 2028
Enrollment
150 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cloves syndrome, klippel-trenaunay syndrome, lymphatic malformations, venous malformations